Expression proteomics study to determine metallodrug targets and optimal drug combinations.

Lee RFS, Chernobrovkin A, Rutishauser D, Allardyce CS, Hacker D, Johnsson K, Zubarev RA, Dyson PJ

Sci Rep 7 (1) 1590 [2017-05-08; online 2017-05-08]

The emerging technique termed functional identification of target by expression proteomics (FITExP) has been shown to identify the key protein targets of anti-cancer drugs. Here, we use this approach to elucidate the proteins involved in the mechanism of action of two ruthenium(II)-based anti-cancer compounds, RAPTA-T and RAPTA-EA in breast cancer cells, revealing significant differences in the proteins upregulated. RAPTA-T causes upregulation of multiple proteins suggesting a broad mechanism of action involving suppression of both metastasis and tumorigenicity. RAPTA-EA bearing a GST inhibiting ethacrynic acid moiety, causes upregulation of mainly oxidative stress related proteins. The approach used in this work could be applied to the prediction of effective drug combinations to test in cancer chemotherapy clinical trials.

Affiliated researcher

PubMed 28484215

DOI 10.1038/s41598-017-01643-1

Crossref 10.1038/s41598-017-01643-1

pii: 10.1038/s41598-017-01643-1
pmc: PMC5431558

Publications 9.5.0